No Data
No Data
Express News | Perceptive Advisors LLC Reports 19.5% Stake in Lyra Therapeutics as of Aug 14 Vs 24.3% as of Feb 14- SEC Filing
Lyra Therapeutics Still Sees Potential in Rhinosinusitis Asset Despite Setbacks
HC Wainwright & Co. Reiterates Neutral on Lyra Therapeutics, Maintains $2 Price Target
BTIG Maintains Lyra Therapeutics(LYRA.US) With Hold Rating
Lyra Therapeutics (LYRA) Receives a Hold From BTIG
Lyra Therapeutics | 10-Q: Q2 2024 Earnings Report
No Data
MARKET-TEST-DUMMY OP : Priming?